Log In
BCIQ
Print this Print this
 

ID-LV305, LV305

  Manage Alerts
Collapse Summary General Information
Company Immune Design Corp.
DescriptionLentiviral vector that expresses full-length cancer/testis antigen 1B (NY-ESO-1; CTAG1B)
Molecular Target Cancer/testis antigen 1B (NY-ESO-1) (CTAG1B)
Mechanism of ActionGene therapy
Therapeutic ModalityGene therapy: Viral vector: Lentivirus
Latest Stage of DevelopmentPhase I
Standard IndicationSolid tumors
Indication DetailsTreat solid tumors that express cancer/testis antigen 1B (CTAG1B; NY-ESO-1)
Regulatory Designation U.S. - Orphan Drug (Treat solid tumors that express cancer/testis antigen 1B (CTAG1B; NY-ESO-1))
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

08/10/2015

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today